PhRMA, the trade association for the U.S.'s top drug makers, spent more than $6 million to lobby Congress and the Trump administration in the fourth quarter, (Photo: Shutterstock)
The pharmaceutical industry's leading trade group disclosed Tuesday that it had spent a record $27.5 million on lobbying in 2018, $1.4 million more than in 2009, when Congress and the White House created the Affordable Care Act, the health-care overhaul better known as Obamacare.
The surge in spending by the Pharmaceutical Research and Manufacturers of America came as the industry failed to win a last-minute legislative fix that would have reduced its share of outlays in a popular Medicare program, and as it prepared for what could be its most challenging year in decades.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
